Open AccessIschemic heart disease: Metabolic approaches to management
Author(s) -
Pauly Daniel F.,
Pepine Carl J.
Publication year - 2004
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960270802
Subject(s) - trimetazidine , medicine , ranolazine , carnitine , coronary artery disease , disease , beta oxidation , metabolic disease , pharmacology , cardiology , metabolism
The number of patients with coronary artery disease and its risk factors is increasing in Western nations. New treatments for these patients may soon include a class of agents known as the metabolic modulators. This group of agents consists of the partial fatty acid oxidation inhibitors trimetazidine and ranolazine, as well as dichloroacetate, which promotes carbohydrate utilization. Metabolic modulators also include the nutriceuticals L‐carnitine and D‐ribose. The available evidence regarding the benefits of each of these five agents is reviewed.